FII Holdings

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE2238.1054.8 (+2.51 %)
PREV CLOSE ( ) 2183.30
OPEN PRICE ( ) 2198.55
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1989
TODAY'S LOW / HIGH ( )2181.60 2240.00
52 WK LOW / HIGH ( )1154.7 2355.05
NSE2230.8537.35 (+1.7 %)
PREV CLOSE( ) 2193.50
OPEN PRICE ( ) 2179.35
BID PRICE (QTY) 2230.85 (11)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 149374
TODAY'S LOW / HIGH( ) 2173.60 2247.95
52 WK LOW / HIGH ( )1155.1 2353.95
upfii downfii 
Current Quarter
Prev Quarter
Company Quarter Ended 202312 % of Share Quarter Ended 202309 % of Share Changeupfii

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.